Vaginal Estradiol: What to Expect Week by Week in Your First Month

Is there a week-by-week timeline?

A meta-analysis of estrogen therapy for urogenital atrophy found that all routes of administration appeared effective and that maximum benefit was obtained between 1 and 3 months after the start of treatment [1]. That finding came from uncontrolled case series covering many treatment types, so it does not establish a week-by-week symptom response for vaginal estradiol [1]. A Cochrane review of local estrogen for vaginal atrophy included randomized comparisons lasting at least 12 weeks [3].

What the cream label says for the first month

The estradiol vaginal cream 0.01% label gives a specific usual dosage: 2 to 4 g daily for one or two weeks, then gradually reduced to one half the initial dose for a similar period. After the vaginal mucosa has been restored, a maintenance dose of 1 g one to three times a week may be used [2]. The label says to choose the lowest dose and regimen that controls symptoms, to use the shortest duration consistent with treatment goals, and to reassess periodically [2]. That schedule belongs to the cream; estradiol tablets, rings and softgel inserts are different vaginal products with their own labels and dosing.

What might be felt early

The cream label lists application-site reactions of vulvovaginal discomfort, including burning and irritation, and genital itching, among reactions reported with estrogen and/or progestin therapy; it gives no frequencies [2]. It also lists vaginitis, including vaginal candidiasis, abnormal uterine bleeding or spotting, dysmenorrhea or pelvic pain, breast tenderness, nausea, vomiting, abdominal cramps, bloating, headache, migraine and dizziness [2]. The label says systemic absorption may occur with the cream and that the warnings, precautions and adverse reactions associated with oral estrogen should be taken into account [2].

Bleeding, uterus, and breast cancer

The cream's boxed warning says unopposed estrogen increases the risk of endometrial cancer in a woman with a uterus. Adding a progestin reduces the risk of endometrial hyperplasia, which may be a precursor [2]. The label says undiagnosed persistent or recurring abnormal genital bleeding should be evaluated with adequate diagnostic measures, including endometrial sampling when indicated [2]. The label also contraindicates the cream in women with undiagnosed abnormal genital bleeding, known or suspected breast cancer or a history of it, estrogen-dependent neoplasia, active DVT or PE or a history of these, active arterial thromboembolic disease or a history, liver disease, thrombophilic disorders, anaphylaxis or angioedema to the product, and known or suspected pregnancy [2]. It says, if feasible, estrogens should be discontinued at least 4 to 6 weeks before surgery associated with increased thromboembolism risk or during prolonged immobilization [2].

A small 2006 study followed seven postmenopausal women with breast cancer who were taking aromatase inhibitors and using a vaginal estradiol tablet (Vagifem). Serum estradiol rose from 5 pmol/L or less at baseline to a mean 72 pmol/L at 2 weeks; by 4 weeks it had fallen to less than 35 pmol/L in most women, median 16 pmol/L, with further rises in two women. The authors concluded that vaginal estradiol appeared contraindicated in this setting [4]. This was a tablet study, not a cream study, and it was very small.